<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312208</url>
  </required_header>
  <id_info>
    <org_study_id>TAX_GMA_301</org_study_id>
    <secondary_id>BCIRG 005</secondary_id>
    <nct_id>NCT00312208</nct_id>
  </id_info>
  <brief_title>Docetaxel in Breast Cancer</brief_title>
  <official_title>A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer International Research Group (CIRG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective :

        -  To compare disease-free survival after treatment with docetaxel in combination with
           doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by
           docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive
           axillary lymph nodes.

      Secondary objectives :

        -  To compare toxicity and quality of life between the 2 above-mentioned arms.

        -  To evaluate pathologic and molecular markers for predicting efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)</measure>
    <time_frame>Median follow-up 65 months</time_frame>
    <description>The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death From Any Cause (Overall Survival)</measure>
    <time_frame>Median follow-up of 65 months</time_frame>
    <description>The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3299</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -&gt; T)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, doxorubicin, cyclophosphamide</intervention_name>
    <description>TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel,doxorubicin, cyclophosphamide</intervention_name>
    <description>AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Histologically proven breast cancer. Interval between definitive surgery that includes
             axillary lymph node dissection and registration is less than or equal to 60 days. A
             central pathology review may be performed post randomization for confirmation of
             diagnosis and molecular studies.

          -  Definitive surgical treatment must be either mastectomy, or breast conserving surgery
             with axillary lymph node dissection for operable breast cancer (T1-3, Clinical N0-1,
             M0). Margins of resected specimen from definitive surgery must be histologically free
             of invasive adenocarcinoma and Ductal Carcinoma In Situ (DCIS). Lobular carcinoma
             in-situ does not count as a positive margin.

          -  Histologic examination of the tumor: Invasive adenocarcinoma with at least one
             axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected
             lymph nodes.

          -  Tumor must show negative HER2 neu proto-oncogene overexpression by FISH (Fluorescence
             In Situ Hybridization). Confirmation of non overexpression will be centrally assessed
             by authorized BCIRG (Breast Cancer International Research Group) laboratories prior to
             randomization.

          -  Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to
             randomization. Results must be known at the time of randomization.(Note: Patients
             whose tumor is estrogen receptor negative with progesterone receptor status unknown or
             undetermined, must have the progesterone receptor assayed in order to determine
             hormonal receptor status. Patients whose tumor is progesterone receptor negative with
             estrogen receptor status unknown or undetermined, must have the estrogen receptor
             assayed in order to determine hormonal receptor status).

          -  Karnofsky Performance status index &gt; 80%.

          -  Normal cardiac function must be confirmed by LVEF (Lef Ventricular Ejection Fraction)
             i.e. MUGA (Multi Gated Acquisition) scan or echocardiography and ECG within 3 months
             prior to registration. LVEF result must be above or equal to the lower limit of normal
             for the institution. The ECG results must be within normal limits or show no
             significant abnormalities.

          -  Laboratory requirements: (within 14 days prior to registration)

               -  Hematology:

                    -  Neutrophils &gt; or = 2.0 x 10^9/L

                    -  Platelets &gt; or = 100 x 10^9/L

                    -  Hemoglobin &gt; or = 10 g/dL

               -  Hepatic function:

                    -  Total bilirubin &lt; or = 1 UNL (Upper Normal Limit)

                    -  ASAT (Aspartate Amino Transferase) and ALAT (Alanine Amino Transferase) &lt; or
                       = 2.5 UNL

                    -  Alkaline phosphatase &lt; or = 5 UNL

                    -  Patients with ASAT and/or ALAT &gt; 1.5 x UNL associated with alkaline
                       phosphatase &gt; 2.5 x UNL are not eligible for the study.

               -  Renal function:

                    -  Creatinine &lt; or = 175 µmol/L (2 mg/dL);

                    -  If limit reached, the calculated creatinine clearance should be &gt; or =
                       60mL/min.

          -  Complete staging work-up within 3 months prior to registration. All patients will have
             contralateral mammography, chest X-ray (Posteroanterior and lateral) and/or CT scan
             and/or MRI (Magnetic Resonance Imaging), abdominal ultrasound and/or CT scan
             (computerized tomography) and/or MRI, and bone scan. In case of positive bone scan,
             bone X-ray is mandatory to rule out the possibility of non-metastatic hot spots. Other
             tests may be performed as clinically indicated.

          -  Negative pregnancy test (urine or serum) within 7 days prior to registration for all
             women of childbearing potential.

        Exclusion Criteria :

          -  Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy,
             genetherapy , chemotherapy).

          -  Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.

          -  Prior radiation therapy for breast cancer.

          -  Bilateral invasive breast cancer.

          -  Pregnant, or lactating patients. Patients of childbearing potential must implement
             adequate non-hormonal contraceptive measures during study treatment (chemotherapy and
             tamoxifen therapy) and must have negative urine or serum pregnancy test within 7 days
             prior to registration.

          -  Any T4 or N2 or known N3 or M1 breast cancer.

          -  Pre-existing motor or sensory neurotoxicity of a severity &gt; grade 2 by NCI-CTC
             (National Cancer Institute - Common Toxicity Criteria), version 2.0.

          -  Other serious illness or medical condition:

               -  congestive heart failure or unstable angina pectoris, previous history of
                  myocardial infarction within 1 year from study entry, uncontrolled hypertension
                  or high-risk uncontrolled arrhythmias

               -  history of significant neurologic or psychiatric disorders including psychotic
                  disorders, dementia or seizures that would prohibit the understanding and giving
                  of informed consent

               -  active uncontrolled infection

               -  active peptic ulcer, unstable diabetes mellitus

          -  Past or current history of neoplasm other than breast carcinoma, except for:

               -  curatively treated non-melanoma skin cancer

               -  carcinoma in situ of the cervix

               -  other cancer curatively treated and with no evidence of disease for at least 10
                  years

               -  ipsilateral ductal carcinoma in-situ (DCIS) of the breast

               -  lobular carcinoma in-situ (LCIS) of the breast

          -  Chronic treatment with corticosteroids unless initiated &gt; 6 months prior to study
             entry and at low dose (&lt; 20 mg methylprednisolone or equivalent).

          -  Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should
             be stopped before study entry.

          -  Definite contraindications for the use of corticosteroids.

          -  Concurrent treatment with other experimental drugs. Participation in another clinical
             trial with any investigational not marketed drug within 30 days prior to study entry.

          -  Concurrent treatment with any other anti-cancer therapy.

          -  Current therapy with any hormonal agent such as raloxifene, tamoxifen or other
             selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention.
             Patients must have discontinued these agents prior to randomization.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe AUSSEL</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Nikosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Kallithea</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Montevideo</city>
        <country>Uruguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Cyprus</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
    <country>Uruguay</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2006</study_first_posted>
  <results_first_submitted>October 29, 2009</results_first_submitted>
  <results_first_submitted_qc>February 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2010</results_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -&gt; T)</title>
          <description>AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Docetaxel + Doxorubicin and Cyclophosphamide (TAC)</title>
          <description>TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1649">1649 patients randomized, 1634 patients treated</participants>
                <participants group_id="P2" count="1649">1649 patients randomized 1635 patients treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1477"/>
                <participants group_id="P2" count="1526"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -&gt; T)</title>
          <description>AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Docetaxel + Doxorubicin and Cyclophosphamide (TAC)</title>
          <description>TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1649"/>
            <count group_id="B2" value="1649"/>
            <count group_id="B3" value="3298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt; =65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="784"/>
                    <measurement group_id="B2" value="783"/>
                    <measurement group_id="B3" value="1567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 49 and 35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="689"/>
                    <measurement group_id="B2" value="710"/>
                    <measurement group_id="B3" value="1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; =35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="22" upper_limit="74"/>
                    <measurement group_id="B2" value="50" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="B3" value="50" lower_limit="22" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1649"/>
                    <measurement group_id="B2" value="1649"/>
                    <measurement group_id="B3" value="3298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bosnia And Herzegovina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyprus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uruguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormonal Receptor Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1348"/>
                    <measurement group_id="B2" value="1346"/>
                    <measurement group_id="B3" value="2694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status at Baseline</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>80 - Activity with effort; some signs of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 - Normal activity; minor signs of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 - Normal no complaints; no evidence of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1298"/>
                    <measurement group_id="B2" value="1293"/>
                    <measurement group_id="B3" value="2591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pre-Menopausal or Other age &lt; 50 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="866"/>
                    <measurement group_id="B2" value="863"/>
                    <measurement group_id="B3" value="1729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Menopausal or Other age &gt; 50 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="783"/>
                    <measurement group_id="B2" value="786"/>
                    <measurement group_id="B3" value="1569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Positive Lymph Nodes</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>[0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[1 to 3]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1010"/>
                    <measurement group_id="B2" value="1005"/>
                    <measurement group_id="B3" value="2015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[4 to 10]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="462"/>
                    <measurement group_id="B2" value="456"/>
                    <measurement group_id="B3" value="918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with at least one surgery</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mastectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="955"/>
                    <measurement group_id="B2" value="973"/>
                    <measurement group_id="B3" value="1928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumpectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quadrantectomy/Segmental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>pT1: Tumor &lt; = 2cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="692"/>
                    <measurement group_id="B2" value="668"/>
                    <measurement group_id="B3" value="1360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pT2: Tumor in [ 2 - 5 ]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="824"/>
                    <measurement group_id="B2" value="844"/>
                    <measurement group_id="B3" value="1668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pT3: Tumor &gt; 5cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pT4: Tumor with extension to chest wall/skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pTis: Carcinoma in situ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)</title>
        <description>The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.</description>
        <time_frame>Median follow-up 65 months</time_frame>
        <population>The primary efficacy analysis was performed on the Intent-to-Treat (ITT) population. Although the original Outcome Measure was intended to be presented as median disease free survival time, median time-to-event was not reached in any group; therefore, number of participants with relapse was presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -&gt; T)</title>
            <description>AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel + Doxorubicin and Cyclophosphamide (TAC)</title>
            <description>TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.</description>
          </group>
        </group_list>
        <measure>
          <title>Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)</title>
          <description>The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.</description>
          <population>The primary efficacy analysis was performed on the Intent-to-Treat (ITT) population. Although the original Outcome Measure was intended to be presented as median disease free survival time, median time-to-event was not reached in any group; therefore, number of participants with relapse was presented.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1649"/>
                <count group_id="O2" value="1649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death From Any Cause (Overall Survival)</title>
        <description>The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.</description>
        <time_frame>Median follow-up of 65 months</time_frame>
        <population>The analysis was performed on the Intent-to-Treat (ITT) population. Although the original Outcome Measure was intended to be presented as median survival time, median time-to-event was not reached in any group; therefore, number of participants who died was presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -&gt; T)</title>
            <description>AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel + Doxorubicin and Cyclophosphamide (TAC)</title>
            <description>TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.</description>
          </group>
        </group_list>
        <measure>
          <title>Death From Any Cause (Overall Survival)</title>
          <description>The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.</description>
          <population>The analysis was performed on the Intent-to-Treat (ITT) population. Although the original Outcome Measure was intended to be presented as median survival time, median time-to-event was not reached in any group; therefore, number of participants who died was presented.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1649"/>
                <count group_id="O2" value="1649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" lower_limit="65.64" upper_limit="65.91"/>
                    <measurement group_id="O2" value="202" lower_limit="65.48" upper_limit="65.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <p_value_desc>Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of patients at risk corresponds to the patients who received at least one dose of treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -&gt; T)</title>
          <description>AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Docetaxel + Doxorubicin and Cyclophosphamide (TAC)</title>
          <description>TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="331" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="520" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Coagulation disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hemorrhage Vaginal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Arrhythmia Ventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Effusion Pericardial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Fibrillation Ventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Heart Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Heart Failure Left</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Ischemia myocardial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deaf</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage Retinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Papilledema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Gastro-intestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hemorrhage Rectal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Ulcer Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Syndrom Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Fever (including serious febrile neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Mucous Membrane Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain Biliary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain Chest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Weight Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Liver Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>SGOT Increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>SGPT Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (including neutropenic infection)</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury Accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Edema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Arthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Neoplasm Uterine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Nodule skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Delusions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Emotional Lability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Paralysis Vocal Cord</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy Unintended</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Kidney Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Urinary Tract Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Uterine Fibroid Enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Vaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Effusion Pleural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Fibrosis lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pneumonia Interstitial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Derm Exfoliating</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Erythema Multiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Nail Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Rash Maculopapular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Hemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Deep</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1634" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1629" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="NCI-CTCAE">Anemia</sub_title>
                <description>NCI severity grade was derived based on reported laboratory data</description>
                <counts group_id="E1" subjects_affected="461" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="658" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title vocab="NCI-CTCAE">Neutropenia</sub_title>
                <description>NCI severity grade was derived based on reported laboratory data</description>
                <counts group_id="E1" subjects_affected="1133" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1049" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title vocab="NCI-CTCAE">Thrombocytopenia</sub_title>
                <description>NCI severity grade was derived based on reported laboratory data</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Lacrimation disorder</sub_title>
                <counts group_id="E1" subjects_affected="357" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="370" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="376" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="599" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="555" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="644" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="606" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="339" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="387" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1435" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1334" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1035" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1026" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Taste pervers</sub_title>
                <counts group_id="E1" subjects_affected="480" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="426" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="907" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="742" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Fever (including febrile neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="467" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="433" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="370" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain abdominal</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain back</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain bone</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pain chest</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Weight decrease</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" subjects_affected="370" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="240" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (including neutropenic infection)</sub_title>
                <counts group_id="E1" subjects_affected="573" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="457" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="488" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="417" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="602" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="382" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1328" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1310" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="834" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="587" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Emotion labil</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="334" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="277" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="723" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="482" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" subjects_affected="388" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="437" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menses disorder</sub_title>
                <counts group_id="E1" subjects_affected="489" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="501" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="287" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1601" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="1587" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Derm exfoliating</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="729" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="363" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <counts group_id="E1" subjects_affected="402" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Skin dry</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1635"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1634"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="1635"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs study director</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>publicregistryGMA@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

